Cannabis Law Report

APRIL 21, 2022

The availability of larger quantities of cGMP-compliant MDMA will facilitate ongoing clinical trials and provide for future therapeutic use following anticipated regulatory approvals. in each of the four validation trials with an acceptable yield, which is a noteworthy accomplishment. MEDIA CONTACT .

Clinical Trials 52

Clinical Trials Research and Development Therapy Media 52

Cannabis Law Report

APRIL 8, 2022

as a non-profit organization to fulfill the need to broaden psychedelic research, therapy, and develop legal options for psychedelic medicine. In MAPS’ 36th year, we’ll learn if our second Phase 3 study of MDMA-assisted therapy for PTSD was successful. At 36, MAPS is now older than I was when I started MAPS at age 32.

Clinical Trials 52

Clinical Trials Therapy Research and Development DEA 52

Cannabis Law Report

JANUARY 12, 2022

According to a recent report released by the Psychedelic Science Funders Collaborative, “Oregon’s psilocybin therapy program provides a high-quality model for psychedelic healing in a non-prescription context that could be replicated in other states.”

Research and Development 52

Research and Development Therapy Safety Clinical Trials 52

Cannabis Law Report

JULY 24, 2021

“At Mydecine, we are excited to expand our drug development program to include the improvement of entactogenic compounds,” said Rob Roscow, Chief Scientific Officer. It is our belief that the tailoring of the properties of these compounds will vastly improve their utility to medicine and therapy.

Research and Development 105

Research and Development Clinical Trials Therapy Events 105

MMJ Recs

APRIL 1, 2024

Furthermore, ongoing clinical trials are investigating CBD’s efficacy in treating conditions such as multiple sclerosis, Parkinson’s disease, and substance abuse disorders. CBD Dosage Guidelines for Medical Use Determining the appropriate dosage of CBD for medical use is crucial to ensure optimal efficacy and safety.

CBD 52

CBD Clinical Trials Chronic Pain Epilepsy 52

Cannabis Law Report

JANUARY 31, 2022

This list is available by request to those seeking access to psilocybin through the Special Access Program (SAP), and clinical researchers. Earlier this month, Health Canada added certain psychedelic compounds to the SAP that were previously available only through clinical trials.

Research and Development 52

Research and Development Clinical Trials Packaging Access 52

Cannabis Law Report

JUNE 4, 2021

– Drug Demonstrates Efficacy and Safety in Advanced Prostate Cancer Patients. – Phase 2 Trial Underway. Additionally, this novel antibody conjugate demonstrated very good tolerability during this DLT phase 1 trial. Clinical trial information: NCT03276572 ( [link] ). About AIkido Pharma Inc.

Data 100

Data Research and Development Clinical Trials Therapy 100

Cannabis Law Report

APRIL 13, 2022

North American Industry Leader in Psychedelic Therapy and Research. Complementary businesses combine to create a preeminent North American platform with operations spanning 13 wellness clinics, four research sites and one bioanalytical laboratory. Shared mission of responsibly reintroducing psychedelic therapy to mental healthcare.

Clinical Trials 52

Clinical Trials Research and Development Therapy Treatment 52

SpeedWeed

JULY 6, 2021

The Project on Psychedelics Law and Regulation (POPLAR) is a three-year project aiming to “promote safety, innovation, and equity in psychedelics research, commerce, and therapeutics,” the university said in a press release. The US market for medicinal psychedelics is predicted to grow to $6.85

Policy 52

Policy Law Research and Development Therapy 52

Cannabis Law Report

NOVEMBER 9, 2021

As an institution dedicated to diagnosing and treating serious blood diseases and with the ability to pursue investigational medicines from development to manufacture and clinical trial for patients who have exhausted all approved treatment options, having a cost-effective and rapid production chain is integral to ÚHKT’s mission.

Clinical Trials 52

Clinical Trials Research and Development Therapy Supply Chain 52

Cannabis Law Report

SEPTEMBER 23, 2022

SB 57 – which passed both houses – would have created a pilot program for overdose prevention sites in San Francisco, Oakland, and Los Angeles as an evidence-based intervention to curb drug overdose deaths. The continued criminalization of all drugs and the people who use them increases harms to public health and safety. ABOUT MAPS.

Decriminalization 52

Decriminalization Advocacy Research and Development Education 52

Cannabis Law Report

JUNE 2, 2021

Aggregate testing results will be reported to the director of the summer camp via safeCircle’s integration with CLEARED4, the Company’s pooled surveillance testing program partner, through CLEARED4’s smartphone-based online health safety management and reporting solution. Testing will be conducted from mid-June through end-July.

Clinical Trials 82

Clinical Trials Therapy Research and Development Collective 82

Cannabis Law Report

JULY 9, 2021

The use of psychedelic substances to treat mental illness and physical disorders is known as “psychedelic therapy.” In a typical scenario, psychedelic substances would be used in conjunction with psychotherapy sessions to treat disorders for which other medicinal therapies have failed. Psychedelic therapy is not a fringe phenomenon.

Law 105

Law Therapy Clinical Trials Research and Development 105

Cannabis Law Report

MAY 29, 2022

FDA granted Breakthrough Therapy designation for Spravato in 2013 and ultimately approved it for adults who have not responded to treatment after trying other antidepressant medications. More recently, MDMA therapy has inched closer to FDA approval. Clinical Trials and Human Subject Protections.

Research and Development 52

Research and Development DEA Clinical Trials Therapy 52

Veriheal

APRIL 11, 2022

He also emphasized the fact that medical cannabis programs are now legal in 37 states, as well as four out of five inhabited U.S. I look forward to a time when they are not considered alternative therapies or home remedies but actually first-line therapies,” said the CEO of Zelira, Oludare Odumosu. “We territories. federal law.

Pharmaceutical 104

Pharmaceutical Research and Development DEA Clinical Trials 104

Cannabis Law Report

DECEMBER 2, 2021

Recommendations and rulemaking relating to training and products were placed on an expedited timeline to ensure that facilitators will be trained, and products will be ready for the January 2, 2023, launch of the first state-sponsored psilocybin therapy program in the United States. Core Psilocybin Facilitation Skills (16 Hours).

Law 52

Law Programs Therapy Education 52

Cannabis Law Report

JUNE 7, 2021

NASDAQ: APDN) (Applied DNA or the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, and its program development partner, Evvivax, S.R.L. Hurry, 917-733-5573, sanjay.hurry@adnas.com Program contact: Brian Viscount, 631-240-8877, brian.viscount@adnas.com Web: www.adnas.com Twitter: @APDN.

Clinical Trials 64

Clinical Trials Research and Development Therapy Supply Chain 64

Cannabis Law Report

OCTOBER 22, 2021

The THX-110 program takes a unique approach to cannabinoid formulation using the Entourage Effect hypothesis (i.e., Cannabis oil: TO Pharmaceuticals TO Pharma is developing next-generation cannabinoid therapies for debilitating diseases. VSN16R was shown to be safe and well-tolerated in its Phase I clinical safety trial.

Research and Development 52

Research and Development Pharmaceutical Marijuana Chronic Pain 52

TheAnswerPage

JANUARY 11, 2022

For example, most, if not all, states have legalized the use of medical marijuana to treat specific health conditions for which there is no or only poor quality clinical evidence of efficacy and safety. Who monitors their health and the long-term effects of the marijuana therapy?

Patients 98

Patients Education Marijuana Therapy 98

Cannabis Law Report

JULY 28, 2021

However, prior to committing to a substantial clinical program for that indication, PharmaDrug looked to further expand on the body of existing supportive data for esophageal cancer, while also potentially revealing new, promising cancer indications. ” Next Steps. ” Next Steps.

Research and Development 105

Research and Development Clinical Trials Treatment Pharmaceutical 105

Puff Puff Post

NOVEMBER 5, 2019

5, 2019 /CNW/ – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX: IN; OTCQX: IMLFF), today announced the filing of a Clinical Trial Application (“CTA”) in the Netherlands to initiate a Phase 1 human clinical trial for INM-755 in healthy volunteers. VANCOUVER, Nov.

Clinical Trials 8

Clinical Trials Pharmaceutical Cannabinoids Data 8

Cannabis Law Report

OCTOBER 18, 2021

The THX-110 program takes a unique approach to cannabinoid formulation using the Entourage Effect hypothesis (i.e., TO Pharma is developing next-generation cannabinoid therapies for debilitating diseases. VSN16R was shown to be safe and well-tolerated in its Phase I clinical safety trial. Key Questions Answered.

Research and Development 52

Research and Development Pharmaceutical Chronic Pain Therapy 52

The Cannigma

JULY 1, 2022

However, a result can be statistically significant but not clinically significant–meaning that even though a study may detect a difference on paper, it may make no tangible difference in real-world application. Non-clinical research can help answer questions regarding safety and risk in very powerful ways.

Research and Development 108

Research and Development Data THC Clinical Trials 108

The Joint Blog

APRIL 17, 2020

This study summarizes potential adverse drug events related to THC when combined with other medications Medicinal Use of Marijuana Cannabis has been used widely across North America in various state or provincial medical marijuana programs. However, many interactions may be unavoidable, dose-limiting, or a barrier to THC-based therapy.

Events 48

Events THC Chronic Pain Sleep 48

Puff Puff Post

DECEMBER 28, 2018

We go deep into what this might mean for the future of therapy for Autism Spectrum Disorders (ASD), and how we might see the use of CBD oil for autism. Success rates of up to 80% have been observed for CBD related autism therapy. Beyond alternative therapies, education and medication are the two most accepted ways of treating autism.

Treatment 76

Treatment Oil CBD Therapy 76

Cannabis Law Report

JUNE 4, 2021

Rick, and MAPS, have published hundreds of research papers, articles, and reports over the past several decades in addition to participation in dozens of clinical trials and international studies. David joined the faculty at UC Davis in 2015, where he established a research program at the interface of chemistry and neuroscience.

Research and Development 51

Research and Development Medicine Treatment Pharmaceutical 51

The Cannigma

APRIL 8, 2021

We’ve actually had one or maybe even two cannabis pharmacists on this program before. It’s not a targeted therapy, that’s why it’s so good at symptom relief, but it hasn’t fix much of anything. That there’s not enough information about, there’s not enough clinical trials, and there’s not enough this and that.

Medicine 108

Medicine Cannabinoids Cannabis THC 108